Metropolis Healthcare shares rose 4.5% to 2,162.45 rupees (US$24.37) on October 7, 2025 after reporting a 23% year-on-year revenue growth for Q2 FY26.

Growth was driven by preventive health check-ups and acquisitions, including Core Diagnostics, Scientific Pathology in Agra, and Dr. Ahuja’s Pathology & Imaging Center in Dehradun.

Core Diagnostics improved from breakeven in Q4 FY25 to high single-digit margins in Q2 FY26.

TruHealth Wellness and Specialty segments grew about 25% and 36%, while B2C and B2B revenues rose 16% and 34% year-on-year.

Metropolis remained debt-free with 55 crore rupees (US$6.2 million) net cash and saw sequential and annual EBITDA margin improvement.

🔗 Source: The Economic Times